Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casopitant in neurogenic bladder due to spinal cord injury
NCT00332319Phase 2Terminated
- Sponsor
- GSK
- Start
- Jan 2006
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of casopitant in neurogenic bladder, overactive bladder (OAB), sponsored by GSK. Started Jan 2006; status: terminated.
02
Drugs
casopitant
03
Conditions
neurogenic bladderoveractive bladder (OAB)
Beyond the preview
Go deeper on NCT00332319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00332319.